About Diagnosis and Treatment
Heart, bone and brain scans provide physicians with detailed images enabling accurate identification and diagnosis. Lives can be extended and often saved if early detection is available. The key element needed for these scans is a radioisotope called Technetium-99 (Tc99), a decay product generated by another radioisotope, Molybdenum-99 (Mo99). Having a consistent and reliable source of Mo99 is vital to the 65,000 patients having scans everyday in the United States. Shortages of Mo99 happen with some frequency and cause delays in diagnosis and treatment leaving patients with potentially life threatening illnesses that can’t be evaluated on a time-sensitive basis.
GMIS will be the leading provider of Mo99, the critical isotope in this most-widely used medical imaging process. Through its unique production process, GMIS also produces another important radioisotope, Iodine-131 (I-131), used primarily in thyroid imaging and ablation treatments. GMIS has a solid pipeline of additional products and is focused entirely on innovation and advancement in disease identification and treatment options in nuclear medicine.
GMIS and its wholly-owned subsidiary, Manufacturing Sciences Corporation (MSC), are highly specialized businesses with unique and valuable capabilities. GMIS is the creator of a revolutionary patented system to produce radioisotopes. GMIS just completed 5 years of focused research and development which provided proof of concept and process validation and is now ready to move into development of its volume production.
MSC holds unique radiological licenses and has expansive production facilities with which to serve the needs of GMIS as it brings its radioisotopes to market. MSC was purchased by GMIS on July 1, 2014. As part of the purchase of MSC, GMIS acquired more than 250,000 square feet of production space on almost 20 acres of land. The purchase also included design, engineering and production expertise, significant equipment assets and valuable licenses that uniquely enable GMIS to operate efficiently in its target market.